Whalesbook
The US Food and Drug Administration's Enforcement Report details significant actions taken by the US-based subsidiaries of these Indian pharmaceutical giants. Sun Pharmaceutical Industries Inc, the US arm of Sun Pharma, initiated a Class III nationwide recall on December 30, 2025. This action involves over 24,600 bottles of Fluocinolone Acetonide Solution Topical Solution, cited for "Failed Impurities/Degradation Specifications." Another recall by the same entity, concerning Clindamycin Phosphate USP for acne vulgaris, was initiated on November 26, 2025, also due to "Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay." The USFDA defines a Class III recall as one where the product's use is not likely to cause adverse health consequences.
Cipla's Recall Details
In a separate development, Cipla USA, Inc., based in Warren, New Jersey, commenced a Class II nationwide recall on January 2, 2026. This recall affects 15,221 syringes of Lanreotide Injection, 120 mg/0.5 mL. The reason cited by the USFDA is the "presence of particulate matter." A Class II recall is initiated for products where exposure may lead to temporary or medically reversible health consequences, or where the likelihood of serious adverse health outcomes is minimal. The US remains the world's largest pharmaceutical market, making such recalls closely watched by investors and industry observers alike.